Neutropenia

7
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
1
0
1
3
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

Amgen
NEULASTAApproved
pegfilgrastim
Amgen
2002
U
XOLREMDIApproved
mavorixafor
Unknown Company
CXC Chemokine Receptor 4 Antagonist [EPC]oral2024

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
NEULASTA(Neulasta)Phase 41 trial
Active Trials
NCT00277160Completed852Est. Jan 2005
X4 Pharmaceuticals
2 programs
1
1
MavorixaforPhase 31 trial
MavorixaforPhase 1/21 trial
Active Trials
NCT04154488CompletedEst. Aug 2024
NCT06056297RecruitingEst. Nov 2027
M&
Merck & Co.RAHWAY, NJ
1 program
1
caspofungin acetatePhase 21 trial
Active Trials
NCT00082537Completed100Est. Oct 2006
Pfizer
PfizerNEW YORK, NY
1 program
1
HSP-130Phase 11 trial
Active Trials
NCT02629289Completed153Est. Jun 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AmgenNeulasta
X4 PharmaceuticalsMavorixafor
Merck & Co.caspofungin acetate
X4 PharmaceuticalsMavorixafor
PfizerHSP-130

Clinical Trials (5)

Total enrollment: 1,105 patients across 5 trials

NCT00277160AmgenNeulasta

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

Start: Jun 2002Est. completion: Jan 2005852 patients
Phase 4Completed
NCT06056297X4 PharmaceuticalsMavorixafor

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Start: Jun 2024Est. completion: Nov 2027
Phase 3Recruiting
NCT00082537Merck & Co.caspofungin acetate

MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)

Start: Apr 2004Est. completion: Oct 2006100 patients
Phase 2Completed
NCT04154488X4 PharmaceuticalsMavorixafor

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Start: Oct 2021Est. completion: Aug 2024
Phase 1/2Completed
NCT02629289PfizerHSP-130

A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants

Start: Aug 2015Est. completion: Jun 2016153 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,105 patients
4 companies competing in this space